This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Chobanian A, Bakris GL, Black H, et al. Seventh report on the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206–1252.
Levy B. Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease. Circulation 2004;109:8–13.
Mathews KA, Katholi R, McCreath H, et al. Blood pressure reactivity to psychological stress predicts hypertension in the CARDIA study. Circulation 2004;110:74–78.
SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older person in isolated systolic hypertension. Final result of the Systolic Hypertension in Elderly Program (SHEP). JAMA 1991;265:3255–3264.
Williams B, Poulter NR, Brown MJ, et al. British Hypertensive Society guidelines for hypertension management 2004 (BSH-1V): summary. BMJ 2004;328:634–640.
Hansson L, Zanchetti A, Carruthers SG, et al., for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998;351: 1755–1762.
Apple LJ, Moore JJ, Oberzanek E, et al. DASH Collaborative Research Group. A clinical trial of the effects of dietary pattern on blood pressure. N Engl J Med 1997;336:1117–1124.
Kesteloot H. Epidemeological studies on the relationship between, Na, K, Ca and Mg and arterial blood pressure. J Cardiovasc Pharmacol 1994; 6:S192–S196.
Sacks FM, Sverkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med 2001;344:3–10.
Furberg CD, Wright JT, Davies BR, et al., on behalf of the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensive-converting enzyme inhibitor or calcium channel blockers vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981–2997.
Schmieder RE, Schlaich MP, Klingbeil A, et al. Reversal of left ventricular hypertrophy in essential hypertension: a meta-analysis of randomised double blind studies. Nephrol Dial Transplant 1998;13: 564–569.
Tatti P, Pahor M, Byington RP, et al. Outcome results of the Fosinopril vs Amlodipine Cardiovascular Events Randomised Trial in patients with hypertension and non-insulin dependent diabetes mellitus. Diabetic Care 1998;21:597–602.
Velussi M, Brocco E, Frigato F, et al. Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. Diabetes 1996; 45:216–222.
Staessen JA, et al. Morbidity and mortality in the Syst-Eur Trial. Lancet 1997;350:757–764.
Heart Outcome Prevention Evaluation Study (HOPE). Effects of an angiotensin converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;324:145–153.
Brunner H. Clinical efficacy of olmesartan medoxmil. J Hypertens 2003;21(suppl 2):s43–s46.
Parving H, Lehnhert H, Bröchner-Mortensen J, et al. The effects of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870–878.
Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus. A blood pressure-independent effect. Circulation 2002;106:672–678.
Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effects of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851–860.
Brenner BM, Cooper ME, de Seeuw D, et al. Effects of losartin on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861–869.
Mallion BJ, Siche JP, Lacourciere Y, et al. ABPM comparison of antihypertension profile of the selected ARBs, telmesartan and losartan in patients with mild to moderate hypertension. J Hum Hypertens 1999; 13:657–664.
Dahlof B, Devereux RB, Kjeldsen J, et al. Cardiovascular morbidity and mortality in the Losartan Interventtion for Endpoint reduction in hypertensive study (LIFE): a randomisized trial against atenolol. Lancet 2002;359:995–1003.
Hansson L, Lithell H, Skoog I, et al., for SCOPE Trial. Prague: European Society of Hypertension, Blood Press 2000;9:146–151.
Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockage of renin-angiotensin system in patients with hypertension, microalbuminuria and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000;321:1440–1444.
Brown MJ, Cruickshank JK, Dominiczak AF, et al. Better blood pressure control: how to combine drugs. J Hum Hypertens 2003;17:81–86.
United Kingdom Prospective Diabetic Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 38. BMJ 1998;317:703–713.
Arauz-Pacheo C, Parrot MA, Raskin P, American Diabetes Association. The treatment of hypertension in adult people with diabetes. Diabetes Care 2002;25:134–147.
Rights and permissions
Copyright information
© 2005 Springer-Verlag London Limited
About this chapter
Cite this chapter
(2005). Hypertension. In: Coronary Heart Disease in Clinical Practice. Springer, London. https://doi.org/10.1007/1-84628-135-0_4
Download citation
DOI: https://doi.org/10.1007/1-84628-135-0_4
Publisher Name: Springer, London
Print ISBN: 978-1-85233-936-4
Online ISBN: 978-1-84628-135-8
eBook Packages: MedicineMedicine (R0)